This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bruker's (BRKR) New Buyout to Advance Digital Transformation
by Zacks Equity Research
Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.
Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
by Zacks Equity Research
Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.
Bruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook
by Zacks Equity Research
Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.
Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips
by Zacks Equity Research
According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.
OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.
QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.
Phibro (PAHC) Q3 Earnings Miss Estimates, Gross Margin Up
by Zacks Equity Research
Higher domestic demand and higher average selling prices for dairy products and growth in the companion animal product drive Phibro's (PAHC) Q3 revenues.
Envista (NVST) Q1 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.
BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.
Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.
Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.
Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View
by Zacks Equity Research
Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.
Inari Medical (NARI) Q1 Earnings Top, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) first-quarter results benefit from significant progress made across all its growth drivers.
Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.
CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut
by Zacks Equity Research
CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.
PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.
DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.
Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust
by Zacks Equity Research
Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.
Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.